V
Valneva SE (VALN)
NMS – Real vaqt narxi. Valyuta: USD
6.00
-0.39 (-6.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.97
-0.03 (-0.50%)
Bozor oldidan: May 13, 2026, 8:15 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
6.00
-0.39 (-6.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.97
-0.03 (-0.50%)
Bozor oldidan: May 13, 2026, 8:15 AM EDT
Valneva SE, ixtisoslashgan vaksina kompaniyasi, o'rganilmagan ehtiyojlarga ega bo'lgan yuqumli kasalliklarga qarshi profilaktik vaksinalarni ishlab chiqadi, ishlab chiqaradi va tijoratlashtiradi. U yapon ensefalitiga qarshi faol immünizatsiya uchun ko'rsatilgan Vero hujayra kulturasidan olingan inaktivatsiyalangan yapon ensefaliti vaksinasi IXIARO; Vibrio cholera yoki issiqlikka chidamli toksin ishlab chiqaruvchi enterotoksigenik Escherichia coli bakteriyasi tomonidan chaqirilgan diareyani oldini olish uchun og'iz orqali qabul qilinadigan vaksina DUKORAL; va chikungunya virusi keltirib chiqaradigan kasallikni oldini olish uchun bir martalik, tirik-atenuatsiyalangan vaksina IXCHIQ/ VLA1553ni taklif etadi. Kompaniya, shuningdek, Laym kasalligiga sabab bo'ladigan Borrelia bakteriyasiga qarshi vaksina nomzodi VLA15; Shigella bakteriyalari keltirib chiqaradigan diareyali infeksiya bo'lgan shigellozni oldini olish uchun to'rt valentli bikonyugat vaksina nomzodi S4V2; chivinlarning yuqishi natijasida kelib chiqqan virusli kasallik bo'lgan Zika virusiga qarshi vaksina nomzodi VLA1601; inson metapnevovirusiga qarshi vaksina nomzodi VLA1554; Clostridium difficilening birinchi simptomatik infeksiyasini oldini olishga qaratilgan vaksina nomzodi VLA84; va Epstein-Barr virusi bilan kasallangan bemorlarni davolash uchun vaksina nomzodi VLA2112ni ishlab chiqadi. Mahsulotlarini Qo'shma Shtatlar, Kanada, Germaniya, Avstriya, Shimoliy Yevropa, Buyuk Britaniya, Fransiya, Yevropaning qolgan qismi va xalqaro miqyosda sotadi. Valneva SE 1998 yilda tashkil etilgan va Fransiya, Sen-Erblen shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Hanneke Schuitemaker Ph.D. | Chief Scientific Officer |
| Dr. Juan-Carlos Jaramillo M.D. | Chief Medical Officer |
| Mr. Joshua Drumm Ph.D. | Vice President of Investor Relations |
| Mr. Peter Buhler | Chief Financial Officer |
| Mr. Thomas Lingelbach | President, CEO & Director |
| Mr. Vincent Dequenne | Chief Operating Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-03-26 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-03-23 | 6-K | lymeresults6-kcoverpage.htm |
| 2026-03-18 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-03-17 | 20-F | valn-20251231.htm |
| 2026-03-09 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-03-02 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-02-19 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-02-13 | 6-K | a6-kcoverpagetemplate.htm |
| 2026-02-03 | 6-K | a6-kcoverpagetemplate.htm |
| Ms. Dipal Patel | Chief Commercial Officer |
| Ms. Kendra Wergin | General Counsel & Corporate Secretary |
| Ms. Laetitia Bachelot-Fontaine | VP of Global Communications & European Investor Relations |
| Ms. Petra Pesendorfer | Chief People Officer |